Zoetis to acquire Nexvet Biopharma

Acquisition to strengthen Zoetis’ pipeline in companion animal therapeutics for chronic pain.

Zoetis Inc. and Nexvet Biopharma PLC announced an agreement in which Zoetis, through wholly owned subsidiary Zoetis Bidco, will purchase Nexvet, an innovator in monoclonal antibody (mAb) therapies for companion animals. The purchase price is $6.72 per share, comprising an aggregate equity valuation of approximately $85 million.

All access premium subscription

This content requires a subscription to Feedstuffs in order to access. If you are a paid subscriber, use your email and password to Log In now.

Current Feedstuffs Subscribers: Online and mobile access are now included at no charge to you. To read this article, use your subscriber email and password to log-in to your account (or contact us for assistance in updating your account.)

Not Currently a Subscriber: Subscribe NOW to Feedstuffs and receive our print and/or digital publications, enewsletters and premium online content. Visit Feedstuffs.com and click on Subscribe at the top of the page for more information.

SUBSCRIBE NOW https://circulation.feedstuffs.com/Publications.aspx

TO RENEW YOUR SUBSCRIPTION https://circulation.feedstuffs.com/SubscriptionOffers.aspx

TAGS: Business
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.